For instance, NO-releasing nanoparticles have demonstrated therapeutic benefits in ischemic heart disease and wound healing, while liposomal formulations of iNOS inhibitors have shown efficacy in reducing inflammation in arthritis models. This evidence concerns the gene NOS2 and arthritic joint disease.